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Background: Safety concerns surrounding drug-eluting stents (DES) in 2006 led to questions about the potential bleeding risk of prolonged dual 
antiplatelet therapy for very elderly patients. We evaluated whether treatment selection strategy (DES vs. bare-metal stents [BMS]) for patients aged 
≥ 85 changed after 2006, with a resultant impact on the overall (DES plus BMS) revascularization, mortality and bleeding rates.
Methods: All patients aged ≥85 years who received stents between April 2003 and September 2008 at all non-federal hospitals in Massachusetts 
were classified according to stent type: DES alone, BMS alone, or both. Index procedures were separated into two time periods: Period 1 (P1): April 
2003-August 2006, Period 2 (P2) September 2006-September 2008. Multivariable regression, adjusting for demographic, clinical and procedural 
characteristics, with generalized estimating equations to account for in-hospital clustering, was performed to identify predictors of treatment 
selection for each time period. Revascularization, mortality, and bleeding requiring hospitalization at one year were determined from the procedural 
and vital statistics records and ICD-9 codes.
Results: Of 2435 patients aged ≥85, 54.8%, 38.8% and 6.4% received DES, BMS or both, respectively. DES were used in 70.7% (N=1641) in P1, 
and declined to 33.3% (N=794), in P2. In P1, predictors of BMS selection were emergency procedure (P<0.001), vein graft treatment (P=0.003), 
cancer (P=0.01) and gastrointestinal bleeding (P=0.02) while multivessel treatment (P<0.001) predicted DES use. In P2, each year of age beyond 
85 (p<0.001), congestive heart failure (p<0.001), and STEMI (p<0.001) predicted BMS selection, while prior PCI (P<0.001) and multilesion 
treatment (P=0.01) predicted DES. Overall, 1-year revascularization, mortality and bleeding rates for P1 vs. P2 were 6.0% vs. 7.2%, 18.0% vs. 18.0%, 
and 11.2% vs. 11.6% (P=NS for all comparisons).
Conclusions: DES use in the extreme elderly declined after 2006 and for each year of age beyond 85 and declined further in the later period. The 
change in treatment strategy after 2006 did not impact overall mortality, bleeding, or revascularization rates.
